1. Scrip
  2. >>Business
  3. >>Financing

Lucky No. 13? Artiva Goes Public, Rises In First Day Of Trading

Average Biopharma Return Is -22.3% So Far In 2024

 
• By Mandy Jackson

Artiva grossed $167m by selling more shares than previously planned, but at a significantly lower price per share than it proposed earlier in the week, to fund its NK cell therapy programs.

IPO abrivation on solid background with glittery text
Artiva launched the 13th biopharma IPO in the US in 2024 • Source: Shutterstock

Artiva Biotherapeutics, Inc.’s initial public offering late on 18 July reflected the mixed bag that the IPO market has become. To get the offering through the IPO window at a time when first-time offerings by biopharmaceutical companies are generating a negative average return, Artiva needed to sell a higher number of shares than planned at a lower price than it proposed earlier in the week.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Trump’s Tariff Rollercoaster Keeps Pharma On Edge

 
• By Jessica Merrill

The rollout of Trump’s tariff plan has been a policy whiplash, but despite a 90-day pause on tariffs, it appears the US president is still holding a grudge with industry over drug pricing.

Trump’s Tariffs Add To European Warning Of $100bn US Exodus

 
• By Andrew McConaghie

European pharma leaders want to see a deal so that no tariffs are imposed on medicines – but they also want the European Union to urgently rethink its sector policies that they believe will lead to massive investment loss.

Will Irish Eyes Still Be Smiling When Trump Tariffs Hits Pharma?

 
• By Kevin Grogan

The US president's most recent comments suggest tariffs on pharma are imminent and Ireland has the most to lose.